Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Trial of Menin-inhibitor Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory KMT2A-r/NUP98-r/NPM1-m Acute Leukemia

NCT06376162 is registered in ClinicalTrials.gov with PedAL BCU, LLC as lead sponsor.

NCT NCT06376162
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06376162 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Trial of Menin-inhibitor Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory KMT2A-r/NUP98-r/NPM1-m Acute Leukemia
Lead sponsor
PedAL BCU, LLC
Phase
Phase 1
Overall status
Recruiting
Start date
March 18, 2025
Completion date
March 31, 2033
Enrollment
20 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory kmt2a-r acute leukemia, relapsed/refractory npm1-m acute leukemia, relapsed/refractory nup98-r acute leukemia